Receiver operator characteristic (ROC) curve of mean value DAS28(ESR) in predicting the development of type 2 diabetes (T2D).

<p>Receiver operator characteristic (ROC) curve of mean value DAS28(ESR) in predicting the development of type 2 diabetes (T2D).</p

Logistic regression analysis for prediction of new-onset impaired fasting glucose.

<p>Logistic regression analysis for prediction of new-onset impaired fasting glucose.</p

Logistic regression analysis for prediction of new-onset type 2 diabetes.

<p>Logistic regression analysis for prediction of new-onset type 2 diabetes.</p

Study design.

<p>* In the pre-recruitment screening phase, patients were excluded if presented: 1) past diagnosis of T2D previously performed by a physician <i>or</i> 2) current or past treatment with antidiabetic medications (including oral antidiabetic drugs and insulin); 3) fasting plasma glucose (FPG) ≥ 126 mg/dL in at least two separate occasions. ** In the recruitment screening phase patients were excluded if fasting plasma glucose (FPG) ≥ 126 mg/dL.</p

Demographic and clinical characteristics of the study cohort.

<p>Demographic and clinical characteristics of the study cohort.</p

Receiver operator characteristic (ROC) curve of mean value DAS28(ESR) in predicting the development of type 2 diabetes (T2D).

<p>Receiver operator characteristic (ROC) curve of mean value DAS28(ESR) in predicting the development of type 2 diabetes (T2D).</p

Predictive factors of new CVEs onset.

<p>Predictive factors of new CVEs onset.</p

Therapeutic strategies of the enrolled patients at the first visit.

<p>Therapeutic strategies of the enrolled patients at the first visit.</p

Baseline clinical characteristics.

<p>Baseline clinical characteristics.</p

Effectiveness and disease activity evaluation in the enrolled patients.

<p>This Figure shows: A) and B) the progressive reduction of both DAS28 and SDAI values; C) the disease activity at the first observation and after 12 months of follow up, respectively; E) the EULAR response criteria after 12 months of follow up.</p